Topic prioritisation
Showing 1 to 2 of 2
| Title | Prioritisation programme | Decision | Decision date |
|---|---|---|---|
| Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312] | Medicines evaluation | Not selected | |
| Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134] | None selected | Not selected |